Fig. 7
From: Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection
CAA contributes weakly to PET cortical positivity. In amyloid phase 3 cases, where cortical neuritic plaque load is borderline (Panel a), PET assessment as abnormal is more likely (P = 0.0001, Kuskal Wallis test) in the presence of CAA (Panel b) and SUVR is elevated (Panel c, P < 0.05 Spearman). Panel d. Probability of positive BIE assessment for all subjects demonstrating that this analysis is only possible in cases with a modest plaque burden (Moderate or phase 3 cases) because of a lack of amyloid angiopathy in phase 0–2 and certain cortical positivity due to abundant cortical neuritic plaques in Phase 4 and 5. Panel e. A similar pattern if observed with regional analysis (frontal, temporal, parietal and striatum). It is likely that this effect is subtle and additive to a neocortical plaque burden already close to the threshold. Boxes represent mean +/- 1 standard error and whiskers represent 95% confidence interval. Open circles represent outlier values and asterisks represent extreme values (see Materials and methods for details)